Skip to main content
. 2022 Jan 13;28(3):380–395. doi: 10.3350/cmh.2021.0366

Figure 1.

Figure 1.

The key benefit-risk summary table with number needed to treat approach for (A) statins and (B) aspirin on chemoprevention of hepatocellular carcinoma.